Company research
CURIS INC
CIK 1108205Updated Nov 11, 2026
SecurityCRIS · NASDAQ · equity
CRIS price & chart
Loading TradingView…
NASDAQ:CRIS on TradingView ↗About the company
We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor. Our monotherapy and combination studies of emavusertib in AML are substantially complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration, or FDA, for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).
In the news
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) News provided by Curis, Inc. Oct 03, 2025, 16:00 ET Share this article Share to X Share this article Share to X LEXINGTON, Mass. , Oct. 3, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a biotechnology company focused on the dev ↗
Recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
DEF 14A filing
PRE 14A filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 27,641,000Source | 42,473,000Source | 18,970,000Source | 29,234,000Source | 50,413,000Source | 29,686,000Source | 39,326,000Source | 62,024,000Source | 19,966,000Source | 41,265,000Source | 77,282,000Source | 108,848,000Source |
| Property, Plant and Equipment, NetUSD | 98,000Source | 246,000Source | 46,000Source | 130,000Source | 308,000Source | 54,000Source | 172,000Source | 370,000Source | 62,000Source | 231,000Source | 434,000Source | 689,000Source |
| GoodwillUSD | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 9,051,000Source | 20,854,000Source | 5,073,000Source | 10,138,000Source | 9,996,000Source | 15,001,000Source | 20,282,000Source | 29,956,000Source | 5,061,000Source | 19,997,000Source | 26,681,000Source | 19,658,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,243,000Source | 2,978,000Source | — | 2,752,000Source | 2,546,000Source | — | 2,315,000Source | 2,154,000Source | 0Source | 3,349,000Source | 2,794,000Source | 2,975,000Source |
| Assets, CurrentUSD | 13,907,000Source | 26,937,000Source | 6,724,000Source | 14,419,000Source | 34,524,000Source | 16,611,000Source | 24,811,000Source | 46,066,000Source | 6,915,000Source | 26,385,000Source | 60,908,000Source | 92,119,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,613,000Source | 3,105,000Source | 1,107,000Source | 1,529,000Source | 3,618,000Source | 1,610,000Source | 2,214,000Source | 3,192,000Source | 1,854,000Source | 3,039,000Source | 1,780,000Source | 3,521,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,221,000Source | 3,461,000Source | 1,206,000Source | 2,543,000Source | 3,752,000Source | 1,552,000Source | 2,857,000Source | 2,704,000Source | 1,890,000Source | 3,163,000Source | 3,056,000Source | 4,401,000Source |
| Other Assets, NoncurrentUSD | 1,889,000Source | 2,303,000Source | 2,012,000Source | 2,616,000Source | 2,303,000Source | 1,943,000Source | 1,960,000Source | 3,358,000Source | 1,573,000Source | 1,960,000Source | 3,358,000Source | 2,022,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 42,332,000Source | 51,208,000Source | 14,275,000Source | 43,220,000Source | 51,107,000Source | 16,979,000Source | 45,933,000Source | 52,562,000Source | 14,504,000Source | 47,263,000Source | 57,612,000Source | 62,296,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 127,000Source | 60,000Source | 19,000Source | 107,000Source | 59,000Source | 400,000Source | 105,000Source | 59,000Source | 129,000Source | 85,000Source | 59,000Source | 966,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,266,737,000Source | -1,230,181,000Source | -1,280,161,000Source | -1,259,008,000Source | -1,220,089,000Source | -1,271,580,000Source | -1,250,415,000Source | -1,208,286,000Source | -1,247,381,000Source | -1,239,799,000Source | -1,196,410,000Source | -1,148,997,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 0Source | — | — | 42,000Source | — | — | 338,000Source | — | 0Source | 229,000Source | -186,000Source |
| Stockholders' Equity Attributable to ParentUSD | -14,691,000Source | -8,735,000Source | 4,695,000Source | -13,986,000Source | -694,000Source | 12,707,000Source | -6,607,000Source | 9,462,000Source | 5,462,000Source | -5,998,000Source | 19,670,000Source | 46,552,000Source |
| Additional Paid in Capital, Common StockUSD | 1,251,919,000Source | 1,221,386,000Source | 1,284,837,000Source | 1,244,915,000Source | 1,219,294,000Source | 1,283,887,000Source | 1,243,703,000Source | 1,217,351,000Source | 1,252,714,000Source | 1,233,716,000Source | 1,215,792,000Source | 1,194,769,000Source |
| Liabilities and EquityUSD | 27,641,000Source | 42,473,000Source | 18,970,000Source | 29,234,000Source | 50,413,000Source | 29,686,000Source | 39,326,000Source | 62,024,000Source | 19,966,000Source | 41,265,000Source | 77,282,000Source | 108,848,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 19,912,000Source | 22,034,000Source | 13,675,000Source | 19,372,000Source | 19,366,000Source | 14,974,000Source | 20,117,000Source | 11,303,000Source | 14,076,000Source | 19,027,000Source | 13,517,000Source | 10,013,000Source |
| Operating Lease, Liability, CurrentUSD | 1,228,000Source | 1,292,000Source | 1,044,000Source | 1,265,000Source | 1,249,000Source | 1,229,000Source | 1,301,000Source | 1,349,000Source | 1,190,000Source | 1,336,000Source | 1,305,000Source | 1,141,000Source |
| Accounts Payable, CurrentUSD | 4,445,000Source | 3,818,000Source | 5,388,000Source | 4,097,000Source | 2,449,000Source | 6,742,000Source | 5,104,000Source | 3,628,000Source | 5,612,000Source | 3,024,000Source | 3,172,000Source | 3,193,000Source |
| Operating Lease, Liability, NoncurrentUSD | 740,000Source | 1,968,000Source | 0Source | 1,044,000Source | 2,309,000Source | 108,000Source | 1,338,000Source | 1,137,000Source | 428,000Source | 1,618,000Source | 1,489,000Source | 2,800,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 7,288,000Source | 8,141,000Source | 7,243,000Source | 6,657,000Source | 6,741,000Source | 7,003,000Source | 6,478,000Source | 6,326,000Source | 7,274,000Source | 7,111,000Source | 9,040,000Source | 5,679,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 9,100,000Source | 20,900,000Source | 5,100,000Source | 10,100,000Source | 28,400,000Source | 15,000,000Source | 20,300,000Source | 40,700,000Source | 5,100,000Source | 20,000,000Source | 56,300,000Source | 85,600,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Long-term Debt, Current MaturitiesUSD | 6,951,000Source | — | — | 7,353,000Source | — | — | 7,234,000Source | — | 0Source | 7,556,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 575,000Source | 1,164,000Source | 4,018,000Source | 5,927,000Source | 6,000,000Source | 6,752,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 0Source | -1,034,000Source | 1,032,000Source | 555,000Source | -181,000Source | -249,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -9,001,000Source | -7,252,000Source | -27,201,000Source | -39,563,000Source | -38,434,000Source | -54,337,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 2,500,000Source | 29,442,000Source | 37,786,000Source | 33,023,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 416,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 18,941,000Source | 7,537,000Source | 9,765,000Source | 3,437,000Source | 7,580,000Source | 867,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 9,940,000Source | 285,000Source | -14,936,000Source | -6,684,000Source | 6,932,000Source | -20,447,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 9,595,000Source | 21,398,000Source | 5,617,000Source | 10,682,000Source | 15,545,000Source | 20,826,000Source | 5,605,000Source | 20,541,000Source | 27,225,000Source | 20,293,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 453,000Source | 1,534,000Source | 461,000Source | 2,359,000Source | 4,112,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 924,000Source | 1,384,000Source | 569,000Source | 1,135,000Source | 575,000Source | 1,164,000Source | 4,018,000Source | 5,927,000Source | 6,000,000Source | 6,752,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 9,100,000Source | 20,900,000Source | 5,100,000Source | 10,100,000Source | 15,000,000Source | 20,300,000Source | 5,100,000Source | 20,000,000Source | 56,300,000Source | 85,600,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | 27,189,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 3,653,000Source | 3,753,000Source | 3,226,000Source | 3,526,000Source | 5,070,000Source | 3,984,000Source | 14,046,000Source | 16,790,000Source | 18,647,000Source | 19,648,000Source |
| GoodwillUSD | — | — | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Investment Income, InterestUSD | — | — | 80,000Source | 325,000Source | 62,000Source | 92,000Source | 77,000Source | 93,000Source | 316,000Source | 1,768,000Source | 2,938,000Source | 1,119,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 5,000Source | -42,000Source | — | — | — | — | — | -229,000Source | 415,000Source | -77,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,729,000Source | -10,092,000Source | -8,581,000Source | -8,593,000Source | -24,199,000Source | -10,616,000Source | -7,582,000Source | -43,389,000Source | -47,413,000Source | -56,672,000Source |
| Nonoperating Income (Expense)USD | — | — | -805,000Source | 475,000Source | 1,359,000Source | -342,000Source | -12,680,000Source | -459,000Source | -1,869,000Source | 1,153,000Source | 919,000Source | -3,652,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | 0Source | 0Source | 18,098,000Source | 70,340,000Source | 62,000,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 18,941,000Source | 10,000,000Source | 15,352,000Source | 12,023,000Source | 14,117,000Source | 5,594,000Source |
| Operating Lease, Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,176,000Source | 2,931,000Source | 0Source | 2,749,000Source | 0Source | 2,380,000Source | 9,443,000Source | 10,908,000Source | 10,023,000Source | 10,162,000Source |
| Operating Income (Loss)USD | — | — | -6,924,000Source | -10,567,000Source | -9,940,000Source | -8,251,000Source | -11,519,000Source | -10,157,000Source | -5,713,000Source | -44,542,000Source | -48,332,000Source | -53,020,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,729,000Source | -10,092,000Source | -8,581,000Source | -8,593,000Source | -24,199,000Source | -10,616,000Source | -7,582,000Source | -43,389,000Source | -47,413,000Source | -56,672,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.49Source | -1.7Source | -4.02Source | -13.61Source | -1.25Source | -1.25Source | -0.58Source | -6.88Source | -8.96Source | 0.61Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.49Source | -1.7Source | -4.02Source | -13.61Source | -1.25Source | -1.25Source | -0.58Source | -6.88Source | -8.96Source | 0.61Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 15,680,178Source | 5,940,924Source | 2,135,906Source | 631,475Source | 19,363,478Source | 8,493,886Source | 13,164,032Source | 6,306,284Source | 5,293,294Source | 93,392,515Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 15,680,178Source | 5,940,924Source | 2,135,906Source | 631,475Source | 19,363,478Source | 8,493,886Source | 13,164,032Source | 6,306,284Source | 5,293,294Source | 93,392,515Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 10,100,000Source | 13,498,000Source | 9,940,000Source | 11,000,000Source | 11,519,000Source | 12,537,000Source | 42,345,000Source | 55,450,000Source | 58,355,000Source | 63,182,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 8,000Source | 59,000Source | 169,000Source | 203,000Source | 255,000Source | 233,000Source |
| General and Administrative ExpenseUSD | — | — | 3,653,000Source | 3,753,000Source | 3,226,000Source | 3,526,000Source | 5,070,000Source | 3,984,000Source | 14,046,000Source | 16,790,000Source | 18,647,000Source | 19,648,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 80,000Source | 325,000Source | 62,000Source | 92,000Source | 77,000Source | 93,000Source | 316,000Source | 1,768,000Source | 2,938,000Source | 1,119,000Source |
| Nonoperating Income (Expense)USD | — | — | -805,000Source | 475,000Source | 1,359,000Source | -342,000Source | -12,680,000Source | -459,000Source | -1,869,000Source | 1,153,000Source | 919,000Source | -3,652,000Source |
| Operating Lease, Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-298203
- Gross proceeds
- 5600000.0
- Net proceeds
- 5236000.0
- Deal price
- 1.5
- Shares
- 3733333
- Offering price
- $1.50
- Ticker
- CRIS
Registration 333-293470
Registration 333-289456
Filing attachments
tm2627615d1_ex4-1.htm · 8-K · 2026-10-19
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗tm2627615d1_ex4-2.htm · 8-K · 2026-10-19
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗tm2627615d1_ex4-3.htm · 8-K · 2026-10-19
Exhibit 4.3 AMENDMENT TO COMMON STOCK PURCHASE WARRANTS This AMENDMENT TO COMMON STOCK PURCHASE WARRANTS (this “Amendment”) is entered into as of October 19, 2026, by and between Curis, Inc., a Delaware corporation (the “Company”), and [ ] (the “Holder”). WHEREAS, the Company issued to the Holder those certain [Series A Common Stock Purchase Warrants (the “Series A Warrants”) and Series C Common Stock Purchase Warrants (the “Series C Warrants” and, together with the Series A Warrants, the “J…
Read attachment ↗tm2627615d1_ex4-4.htm · 8-K · 2026-10-19
Exhibit 4.4 NOTICE AND CONSENT October 19, 2026 WHEREAS, Curis, Inc., a Delaware corporation (the “Company”), issued a Warrant to Purchase Common Stock (the “Warrant”) to the undersigned (the “Holder”) on August 14, 2026 with an exercise price per share of Common Stock under the Warrant of $1.75, subject to adjustment as set forth therein (the “Exercise Price”). WHEREAS, Section 3(g) of the Warrant provides that the Company may at any time during the term of the Warrant, subject to the prior…
Read attachment ↗ex41formofpre-fundedwarrant.htm · 8-K · 2025-03-28
EX-4.1 2 ex41formofpre-fundedwarrant.htm EX-4.1 Document EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES …
Read attachment ↗ex42-formofcommonstockwarr.htm · 8-K · 2025-03-28
EX-4.2 3 ex42-formofcommonstockwarr.htm EX-4.2 Document EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES A…
Read attachment ↗